Cascadian Therapeutics (CASC) Reports Q3 Loss of $0.28/Share

Cascadian Therapeutics (NASDAQ: CASC) reported Q3 EPS of ($0.28), versus ($0.52) reported last year.

Cascadian Therapeutics expects operating expenses in 2017 to be slightly higher than in 2016, primarily due to an increase in activities related to the ongoing worldwide HER2CLIMB pivotal trial. Cash used in operations for 2017 is expected to be approximately $50.0 million to $54.0 million. Cascadian Therapeutics believes the above financial guidance to be correct as of the date hereof and is providing the guidance as a convenience to investors and assumes no obligation to update it

For earnings history and earnings-related data on Cascadian Therapeutics (CASC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c